Mission

The European Network for Translational Research in Atrial Fibrillation (EUTRAF) consortium aims to develop approaches for increasing knowledge of the arrhythmogenic substrate, with the ultimate goal of developing novel treatments and diagnostic tools for atrial fibrillation.

To do this, the goals of the consortium are to: identify cellular and molecular interactions between stromal and parenchumal cells in atrial fibrillation; identify and validate ion channels and transporters for the treatment of persistent atrial fibrillation; identify etiology-specific mechanisms in atrial fibrillation; identify and test in the pre-clinical setting new “upstream” therapeutic targets for sustained atrial fibrillation; translate the genetic contributors to atrial fibrillation into therapeutic targets; develop new diagnostic tools; characterize atrial substrate and conduct proof-of-concept therapeutic clinical studies; develop an IT infrastructure to accelerate knowledge discovery.

Consortium History

November 2010--Project Launch, January 2011--Project Kick off meeting at St. George's University London, October 2011--Month 12 meeting at University of Maastricht, June 2013--Svetlana Reilly Recieves Prize for oral presentation. November 2013--3rd Annual Meeting & project review. February 2014--First issue of EUTRAF newsletter circulated. November 2014--4th annual meeting hosted by Universitaetsklinkikum Essen.

Financing

The "European Network for translational research in atrial fibrillation" (EUTRAF) was granted a total amount of 12 M euros for integrated research through EU FP7 in order to explore disease mechanisms and to develop better diagnostic means and new therapies in patients with atrial fibrillation.

Data Sharing

One of the workstreams aims to create an IT infrastructure that is capable of combining and sharing biomarker data associated with atrial fibrillation.

Sponsors & Partners